Stock Track | REMEGEN Soars 8.29% as Telitacicept gMG Study Selected for Prestigious Medical Conference

Stock Track

Sep 18

REMEGEN (09995) shares surged 8.29% to HK$115 in intraday trading, with a robust trading volume of HK$222 million. The significant uptick comes on the heels of a major announcement regarding the company's innovative drug, Telitacicept.

The biotech firm revealed that clinical data from the China Phase III study of Telitacicept (RC18, brand name: Tavira®) for treating generalized myasthenia gravis (gMG) has been selected for oral presentation at the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting (AANEM). Specifically, the 48-week open-label extension (OLE) study data, which validates the drug's long-term efficacy, will be presented at the prestigious conference scheduled for October 29 to November 1 in San Francisco, California.

Adding to investor optimism, REMEGEN also highlighted its global exclusive licensing agreement with Pfizer Inc. (formerly Seattle Genetics) during a recent earnings briefing. The agreement, established in August 2021, grants Pfizer the global development and commercialization rights for Disitamab vedotin (RC48) outside REMEGEN's territory. The company confirmed that Pfizer is advancing RC48's overseas clinical trials as planned, potentially opening up significant market opportunities for REMEGEN's innovative therapies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1183877527"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183877527\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183877527?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 09:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183877527","market":"nz","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 8.29% as Telitacicept gMG Study Selected for Prestigious Medical Conference","media":"Stock Track","content":"<p>REMEGEN (09995) shares surged 8.29% to HK$115 in intraday trading, with a robust trading volume of HK$222 million. The significant uptick comes on the heels of a major announcement regarding the company's innovative drug, Telitacicept.</p>\n\n<p>The biotech firm revealed that clinical data from the China Phase III study of Telitacicept (RC18, brand name: Tavira®) for treating generalized myasthenia gravis (gMG) has been selected for oral presentation at the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting (AANEM). Specifically, the 48-week open-label extension (OLE) study data, which validates the drug's long-term efficacy, will be presented at the prestigious conference scheduled for October 29 to November 1 in San Francisco, California.</p>\n\n<p>Adding to investor optimism, REMEGEN also highlighted its global exclusive licensing agreement with Pfizer Inc. (formerly Seattle Genetics) during a recent earnings briefing. The agreement, established in August 2021, grants Pfizer the global development and commercialization rights for Disitamab vedotin (RC48) outside REMEGEN's territory. The company confirmed that Pfizer is advancing RC48's overseas clinical trials as planned, potentially opening up significant market opportunities for REMEGEN's innovative therapies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 8.29% as Telitacicept gMG Study Selected for Prestigious Medical Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 8.29% as Telitacicept gMG Study Selected for Prestigious Medical Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-18 09:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995) shares surged 8.29% to HK$115 in intraday trading, with a robust trading volume of HK$222 million. The significant uptick comes on the heels of a major announcement regarding the company's innovative drug, Telitacicept.</p>\n\n<p>The biotech firm revealed that clinical data from the China Phase III study of Telitacicept (RC18, brand name: Tavira®) for treating generalized myasthenia gravis (gMG) has been selected for oral presentation at the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting (AANEM). Specifically, the 48-week open-label extension (OLE) study data, which validates the drug's long-term efficacy, will be presented at the prestigious conference scheduled for October 29 to November 1 in San Francisco, California.</p>\n\n<p>Adding to investor optimism, REMEGEN also highlighted its global exclusive licensing agreement with Pfizer Inc. (formerly Seattle Genetics) during a recent earnings briefing. The agreement, established in August 2021, grants Pfizer the global development and commercialization rights for Disitamab vedotin (RC48) outside REMEGEN's territory. The company confirmed that Pfizer is advancing RC48's overseas clinical trials as planned, potentially opening up significant market opportunities for REMEGEN's innovative therapies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1183877527","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183877527","pubTimestamp":1758160580,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN (09995) shares surged 8.29% to HK$115 in intraday trading, with a robust trading volume of HK$222 million. The significant uptick comes on the heels of a major announcement regarding the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|瑞美根大涨8.29%Telitacicept gMG研究入选著名医学会议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN (09995) shares surged 8.29% to HK$115 in intraday trading, with a robust trading volume of HK$222 million. The significant uptick comes on the heels of a major announcement regarding the company's innovative drug, Telitacicept.\nThe biotech firm revealed that clinical data from the China Phase III study of Telitacicept (RC18, brand name: Tavira®) for treating generalized myasthenia gravis (gMG) has been selected for oral presentation at the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting (AANEM). Specifically, the 48-week open-label extension (OLE) study data, which validates the drug's long-term efficacy, will be presented at the prestigious conference scheduled for October 29 to November 1 in San Francisco, California.\nAdding to investor optimism, REMEGEN also highlighted its global exclusive licensing agreement with Pfizer Inc. (formerly Seattle Genetics) during a recent earnings briefing. The agreement, established in August 2021, grants Pfizer the global development and commercialization rights for Disitamab vedotin (RC48) outside REMEGEN's territory. The company confirmed that Pfizer is advancing RC48's overseas clinical trials as planned, potentially opening up significant market opportunities for REMEGEN's innovative therapies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}